Creative Medical Technology Holdings, Inc. (CELZ) Bundle
An Overview of Creative Medical Technology Holdings, Inc. (CELZ)
General Summary of the Company
Creative Medical Technology Holdings, Inc. (CELZ) is a commercial-stage biotechnology company dedicated to developing and commercializing innovative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. The company was incorporated on December 3, 1998, originally under the name Jolley Marketing, Inc. Following a recapitalization and reverse merger in May 2016, it adopted its current name to better reflect its business focus. CELZ specializes in developing treatments utilizing re-programmed stem cells for various medical conditions, including erectile dysfunction and chronic lower back pain.
As of 2024, the company primarily markets the CaverStem® and FemCelz® disposable kits, which are used in autologous procedures to treat erectile dysfunction and female sexual dysfunction, respectively. The company has expanded its research scope, including therapies for type 1 diabetes and other diseases through its subsidiaries, namely ImmCelz, Inc., StemSpine, Inc., and AlloCelz LLC.
In 2024, CELZ has not reported significant revenue from its products, indicating that the company is still in the developmental phase for many of its therapies.
Company's Financial Performance in the Latest Financial Reports
As of September 30, 2024, Creative Medical Technology Holdings, Inc. reported no revenues for the three months ended September 30, 2024, compared to $6,000 for the same period in 2023. For the nine months ended September 30, 2024, total revenues were $8,000, an increase from $6,000 during the same period in 2023. The cost of goods sold for the nine months ended September 30, 2024, was $3,200, resulting in a gross profit of $4,800, compared to $2,400 in costs and a gross profit of $3,600 for the same period in 2023.
The operating loss for the three months ended September 30, 2024, was $1,109,674, down from a loss of $1,546,785 for the same period in 2023. For the nine months ended September 30, 2024, the operating loss was $3,858,127, slightly higher than the $3,848,293 loss reported in the same period in 2023.
Net loss for the three months ended September 30, 2024, was $1,040,135, compared to a loss of $1,453,952 in 2023. The net loss for the nine months ended September 30, 2024, was $3,639,407, compared to $3,608,000 for the same period in 2023. As of September 30, 2024, the company had available cash and equivalents totaling $6,260,438 and positive working capital of approximately $6,000,532.
Introduction to Company as One of the Leading Companies in the Industry
Creative Medical Technology Holdings, Inc. has positioned itself as a leader in the biotechnology industry, focusing on advanced therapeutic solutions and innovative medical technologies. The company's commitment to utilizing stem cells and immunotherapy places it at the forefront of medical research and treatment options. Recent developments, such as the FDA authorization for expanded access therapy using CELZ-201 for type 1 diabetes prevention, underscore its innovative approach and potential for significant impact in the healthcare sector.
Moreover, CELZ's efforts in developing human insulin-producing cells from induced pluripotent stem cells (iPSC) and its initiatives involving artificial intelligence to enhance patient treatment further demonstrate its leadership in the field. As the company continues to advance its clinical trials and product offerings, it remains a noteworthy entity to watch within the biotechnology landscape.
Mission Statement of Creative Medical Technology Holdings, Inc. (CELZ)
Mission Statement of Creative Medical Technology Holdings, Inc. (CELZ)
The mission statement of Creative Medical Technology Holdings, Inc. (CELZ) serves as a guiding principle for the company, reflecting its commitment to advancing health through innovative biotechnological solutions. The company focuses on developing and commercializing novel biological therapeutics, primarily in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. This mission is significant as it encapsulates the core purpose of the organization and directs its strategic initiatives towards achieving long-term goals.
Core Component 1: Innovation in Biotechnology
At the heart of CELZ's mission is a dedication to innovation. The company emphasizes developing cutting-edge therapies that leverage the latest scientific advancements. For instance, CELZ has made significant strides in stem cell research, particularly with its ImmCelz, Inc. subsidiary, which focuses on reprogramming a patient's immune cells for therapeutic use. This innovative approach aims to provide effective treatments for various conditions, including chronic pain and type 1 diabetes.
As of September 30, 2024, the company reported research and development expenses of approximately $1,928,937 for the nine-month period, reflecting a commitment to advancing its innovative projects.
Core Component 2: Commitment to Quality and Safety
CELZ places a strong emphasis on delivering high-quality and safe products. This commitment is evident in its rigorous research and clinical trials. The company is currently conducting the CELZ-201 ADAPT Chronic Lower Back Pain clinical trial, which has seen an increase in associated costs, amounting to $508,268 for the nine-month period ended September 30, 2024. Such investments underline CELZ's focus on ensuring that its products meet the highest safety and efficacy standards.
Core Component 3: Patient-Centric Approach
The mission statement reflects CELZ's patient-centric philosophy, which prioritizes improving patient outcomes through its therapeutic offerings. By focusing on the needs and experiences of patients, the company aims to enhance the quality of life for individuals suffering from various medical conditions. This approach is complemented by the development of products like CaverStem® and FemCelz®, designed for treating erectile dysfunction and female sexual dysfunction respectively.
As of September 30, 2024, CELZ reported a net loss of $3,639,407, indicating the financial challenges faced while striving to maintain its patient-focused innovation. However, the company continues to explore avenues for growth and development to better serve its patient base.
| Financial Metric | Q3 2024 | Q3 2023 |
|---|---|---|
| Gross Revenue | $8,000 | $6,000 |
| Cost of Goods Sold | $3,200 | $2,400 |
| Net Loss | $3,639,407 | $3,608,000 |
| Research and Development Expenses | $1,928,937 | $1,621,231 |
| Selling, General and Administrative Expenses | $1,846,177 | $2,161,599 |
Vision Statement of Creative Medical Technology Holdings, Inc. (CELZ)
Vision Statement Overview
Creative Medical Technology Holdings, Inc. (CELZ) envisions a future where innovative biotechnology solutions transform patient care. The company's vision focuses on advancing the development of novel biological therapeutics across various medical fields.
Innovative Biotechnology Solutions
CELZ aims to leverage cutting-edge technologies to create effective treatments for chronic conditions. The focus is on immunotherapy, endocrinology, urology, neurology, and orthopedics. As of September 30, 2024, the company reported a net loss of $3,639,407, slightly increased from a loss of $3,608,000 in the same period of 2023.
| Category | 2024 Financials | 2023 Financials |
|---|---|---|
| Net Loss | $3,639,407 | $3,608,000 |
| Research and Development Expenses | $1,928,937 | $1,621,231 |
| Gross Revenue | $8,000 | $6,000 |
| Operating Loss | $3,858,127 | $3,848,293 |
Commitment to Patient-Centric Care
The company’s vision emphasizes a patient-centric approach. By harnessing the potential of stem cell therapies and personalized medicine, CELZ aims to improve the quality of life for patients suffering from debilitating conditions. The company has initiated multiple clinical trials, including the Phase I/II trial for AlloStemSpine™ targeting chronic lower back pain.
Strategic Collaborations and Partnerships
CELZ seeks to establish strategic partnerships to enhance its research capabilities and expand its product offerings. Collaborations with academic institutions and biotech firms are central to its strategy. In 2024, the company reported total cash available of $6,260,438, down from $9,987,058 as of December 31, 2023.
Future Growth and Market Expansion
The vision extends to market expansion through innovative therapies that address unmet medical needs. CELZ is actively pursuing FDA approvals for its therapies, including the recent authorization for expanded access therapy using CELZ-201 for Type I Diabetes.
Conclusion
Creative Medical Technology Holdings, Inc. is dedicated to pioneering advancements in biotechnology, with a vision focused on innovative solutions, patient care, and strategic partnerships. This commitment is reflected in its ongoing clinical trials and financial performance as it navigates the complexities of the biotech industry.
Core Values of Creative Medical Technology Holdings, Inc. (CELZ)
Integrity
The core value of integrity at Creative Medical Technology Holdings, Inc. (CELZ) emphasizes honesty and transparency in all business dealings. This value is critical in building trust with stakeholders, including investors, patients, and regulatory bodies.
In 2024, CELZ demonstrated its commitment to integrity by adhering to stringent regulatory compliance during its clinical trials. The company secured FDA authorization for its therapy using CELZ-201, aimed at managing abnormal glucose tolerance and preventing Type I Diabetes, showcasing its dedication to ethical practices in clinical research.
Innovation
Innovation is a cornerstone of CELZ’s strategy, driving the development of cutting-edge therapies. The company invests significantly in research and development (R&D), which totaled approximately $1.93 million for the nine months ending September 30, 2024, marking a 19% increase from the prior year.
Notably, CELZ successfully generated human induced pluripotent stem cell-derived Islet Cells in June 2024, a breakthrough that positions the company at the forefront of diabetes treatment. This innovation reflects CELZ's commitment to leveraging advanced technologies to address unmet medical needs.
Collaboration
Collaboration is integral to CELZ’s operational ethos, fostering partnerships that enhance its research capabilities and reach. The company has engaged with various clinical research organizations (CROs) to facilitate its clinical trials, including the Phase I/II trial for AlloStemSpine™ Chronic Lower Back Pain, which began in 2024.
Additionally, CELZ's partnership with Greenstone Biosciences Inc. aims to expedite the development of therapies for patients exposed to biological and chemical weapons, illustrating the company's proactive approach to collaborative innovation.
Excellence
CELZ strives for excellence in all aspects of its operations, from clinical trials to patient care. The company reported an operating loss of approximately $3.86 million for the nine months ending September 30, 2024, down slightly from $3.85 million in the same period the previous year, indicating improved operational efficiency.
The positive outcomes from the StemSpine™ pilot study, which demonstrated continued efficacy in treating chronic lower back pain, further underscore CELZ's commitment to delivering high-quality, effective treatments.
| Core Value | Commitment | Recent Example |
|---|---|---|
| Integrity | Honesty and transparency in business | FDA authorization for CELZ-201 therapy |
| Innovation | Investment in R&D and advanced therapies | Generation of human iPSC-derived Islet Cells |
| Collaboration | Partnerships to enhance capabilities | Collaboration with CROs and Greenstone Biosciences |
| Excellence | High standards in operations and patient care | Positive outcomes in StemSpine™ pilot study |
Creative Medical Technology Holdings, Inc. (CELZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Creative Medical Technology Holdings, Inc. (CELZ) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Creative Medical Technology Holdings, Inc. (CELZ)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Creative Medical Technology Holdings, Inc. (CELZ)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.